- Home
- ABVC vs PRLD Comparison
ABVC vs PRLD Comparison
Compare ABVC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- PRLD
- Stock Information
- Founded
- ABVC 2015
- PRLD 2016
- Country
- ABVC United States
- PRLD United States
- Employees
- ABVC N/A
- PRLD N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- ABVC Health Care
- PRLD Health Care
- Exchange
- ABVC Nasdaq
- PRLD Nasdaq
- Market Cap
- ABVC 68.7M
- PRLD 69.1M
- IPO Year
- ABVC N/A
- PRLD 2020
- Fundamental
- Price
- ABVC $2.48
- PRLD $1.57
- Analyst Decision
- ABVC
- PRLD Strong Buy
- Analyst Count
- ABVC 0
- PRLD 3
- Target Price
- ABVC N/A
- PRLD $4.00
- AVG Volume (30 Days)
- ABVC 62.5K
- PRLD 3.7M
- Earning Date
- ABVC 11-03-2025
- PRLD 11-12-2025
- Dividend Yield
- ABVC N/A
- PRLD N/A
- EPS Growth
- ABVC N/A
- PRLD N/A
- EPS
- ABVC N/A
- PRLD N/A
- Revenue
- ABVC $797,916.00
- PRLD $10,500,000.00
- Revenue This Year
- ABVC $735.18
- PRLD N/A
- Revenue Next Year
- ABVC N/A
- PRLD N/A
- P/E Ratio
- ABVC N/A
- PRLD N/A
- Revenue Growth
- ABVC 56.52
- PRLD 250.00
- 52 Week Low
- ABVC $0.40
- PRLD $0.61
- 52 Week High
- ABVC $5.48
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- ABVC 37.24
- PRLD 50.29
- Support Level
- ABVC $2.77
- PRLD $1.50
- Resistance Level
- ABVC $3.06
- PRLD $1.69
- Average True Range (ATR)
- ABVC 0.17
- PRLD 0.18
- MACD
- ABVC -0.03
- PRLD -0.02
- Stochastic Oscillator
- ABVC 14.75
- PRLD 70.38
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.